Pemigatinib combined with immunotherapy and stereotactic body radiation therapy for FGFR2 fusion-positive advanced intrahepatic cholangiocarcinoma with brain metastasis: a Case Report
2024

Pemigatinib and Immunotherapy for Advanced Cholangiocarcinoma

Sample size: 1 publication Evidence: low

Author Information

Author(s): Guo Jiamin, Sun Lingqi, Chen Ye, Ma Ji

Primary Institution: West China Hospital, Sichuan University, Chengdu, Sichuan, China

Hypothesis

Can pemigatinib combined with immunotherapy and stereotactic body radiation therapy effectively treat FGFR2 fusion-positive advanced intrahepatic cholangiocarcinoma with brain metastasis?

Conclusion

The combination therapy of pemigatinib, immunotherapy, and stereotactic body radiation therapy was effective and well-tolerated in a patient with advanced cholangiocarcinoma and brain metastasis.

Supporting Evidence

  • FGFR2 fusions occur in 13%–20% of patients with intrahepatic cholangiocarcinoma.
  • Brain metastasis in advanced intrahepatic cholangiocarcinoma is extremely rare.
  • The patient experienced significant tumor shrinkage after treatment with the combination therapy.

Takeaway

A patient with a rare type of liver cancer had their tumors shrink after receiving a special combination of treatments, including a targeted drug and radiation.

Methodology

The patient was treated with pemigatinib, immunotherapy (tislelizumab), and stereotactic body radiation therapy for brain metastasis.

Potential Biases

The inherent bias of a single-case study may affect the reliability of the results.

Limitations

The study lacks a control group and is based on a single case, limiting the generalizability of the findings.

Participant Demographics

The patient was a 58-year-old male from China.

Digital Object Identifier (DOI)

10.3389/fphar.2024.1509891

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication